Very early onset inflammatory bowel disease (VEOIBD) is IBD that occurs in children under age 6 — sometimes as young as just a few weeks old. At Boston Children’s, we care for these children in our VEOIBD Program. We also see patients of any age who have IBD secondary to an underlying immunodeficiency.
Our approach to VEOIBD
We provide state-of-the-art care that is driven by science, offering personalized therapeutic options led by a collaborative and multidisciplinary team.
This team includes gastroenterologists with specific expertise in diagnosing and managing patients with VEOIBD, as well as immunologists experienced in this condition. We also work with experts from many different specialties throughout Boston Children’s, such as:
- Genetic counselors
- Nutritionists
- Bone marrow transplant experts
- Geneticists
- Surgeons
Together, we create a personalized care plan that is based on the latest research findings and is tailored to your child’s unique needs. This includes an advanced detailed and data-driven immunologic and genetic evaluation, which allows us to better understand the drivers of your child’s condition to offer the highest chance of clinical improvement.
Our areas of innovation
The BCH VEOIBD Program is a leader in identifying novel genetic causes and new approaches to managing VEOIBD. We are also a member of the international VEOIBD Consortium, the largest research consortium in the world focused on bettering our understanding and treating VEOIBD. Our work is supported by federal, foundational and philanthropic funds. Learn about our research.
Conditions we treat
- Very Early Onset Inflammatory Bowel Disease (VEOIBD), including
- VEOIBD - Ulcerative Colitis
- VEOIBD - Crohn’s disease
- VEOIBD - Undefined
- Older-onset IBD with strong suspicion for underlying immune dysregulation
- Older-onset IBD with strong suspicion for underlying monogenic etiology
